All the latest about our company
Meet us at Neuro4D Conference
March 19, 2024attyloid is thrilled to announce its sponsorship of the upcoming annual Neuro4D Conference, a cornerstone event dedicated to advancing research ...
attyloid to showcase innovations in biomarker development at AD/PD™ 2024 conference
February 19, 2024We are excited to announce that attyloid will be presenting at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s ...
Meet us at the Düsseldorf-Jülich Symposium 2023
December 4, 2023Oliver Bannach, CEO of attyloid, will present at the 5th Düsseldorf-Jülich Symposium on Neurodegenerative Diseases, themed "Amyloid, from early aggregation ...
sFIDA Technology Reveals New Insights into Protein Aggregation in Psychotic Disorders
September 5, 2023In a pioneering study that could have wide-reaching implications for psychiatric research, scientists have employed attyloid’s surface-based Fluorescence Intensity Distribution ...
attyloid’s sFIDA Technology Key in Revealing COVID-19’s Potential Neurodegenerative Impact
August 21, 2023A new study has utilized attyloid's cutting-edge Single Molecule Fluorescence Intensity Distribution Analysis (sFIDA) technology to explore how COVID-19 may ...
Recent Study Validates Alzheimer’s Treatment in Beagle Models, Credits sFIDA Technology for Precise Quantification of Tau Aggregates
July 29, 2023In a significant new study focusing on Alzheimer's Disease (AD), researchers have highlighted the disease-modifying effects of RD2, a potential ...
New Publication Highlights Enhancement of attyloid’s sFIDA Technology Through Internal Quality Control Standards
May 10, 2023attyloid's recent publication has outlined the establishment of an internal quality control (IQC) standard aimed at improving the robustness of ...
Meet us at Neuro 4D
April 21, 2023The Neuro4D conference takes place in Mainz, Germany on May 15-16, 2023. With a focus on drug discovery for proteopathic ...
attyloid’s sFIDA Used in Detecting Parkinson’s-Related Biomarkers in Stool Samples
February 2, 2023A recent study published in Nature Parkinson’s Diease has used attyloid's sFIDA technology to measure α-synuclein aggregates in stool, a ...